This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 8
  • /
  • Exploratory analysis shows Olinvyk treated patient...
News

Exploratory analysis shows Olinvyk treated patients are ~50% less likely to experience an AE compared to morphine patients

Read time: 1 mins
Published:11th Aug 2021
Trevena, Inc. announced the publication of an exploratory analysis evaluating the safety of Olinvyk (oliceridine) injection and IV morphine, using data from the Olinvyk Phase III program.

The findings suggest that under equianalgesic conditions, patients receiving Olinvyk were less likely to experience adverse events (AEs) compared to patients treated with morphine.

The publication is titled, “Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase III Randomized Placebo and Active Controlled Trials,” with lead author Gregory B. Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University (DOI: https://doi.org/10.1007/s40122-021-00299-0).

“IV opioids continue to play a key role in post-operative pain management in my practice. As clinicians, we are always focused on achieving the optimal balance of analgesia with minimal risks to our patients,” said Dr. Hammer. “These findings provide useful insight into the benefit-risk profile of Olinvyk and suggest that it can provide morphine-level pain relief with a lower risk of adverse events.”

Publication Key Points : A logistic regression analysis of data from the two Olinvyk Phase III pivotal trials suggested that, at equal levels of analgesia comparing OlinvykK to IV morphine: i. Olinvyk-treated patients were ~50% less likely than morphine-treated patients to experience one or more treatment-emergent AEs of nausea, vomiting, sedation, dizziness, pruritus, or hypoxia. ii. The odds ratio (OR) for a comparison of the effect of treatment with Olinvyk versus morphine was 0.507 for the pooled hard- and soft-tissue studies data (p = 0.009). An OR <1 indicates a lower likelihood of achieving the safety composite endpoint associated with olinvyk treatment versus morphine. the or was 0.499 (p="0.042)" and 0.542 (p="0.121)" for the hard-tissue and soft-tissue studies, respectively.the publication can be found at https: www.trevena.com publications.></1>

Condition: Pain:Moderate to Severe
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.